Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil.

Literature DB >> 9748061

Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil.

R A Hauser¹, A R Malek, R Rosen.

Abstract

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1998 PMID： 9748061 DOI： 10.1212/wnl.51.3.912-a

Source DB: PubMed Journal: Neurology ISSN： 0028-3878 Impact factor: 9.910

Keyword Cloud
Cited

× No keyword cloud information.

8 in total

1. A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing-remitting multiple sclerosis (TIME MS).

Authors: Gina M Remington; Katherine Treadaway; Teresa Frohman; Amber Salter; Olaf Stüve; Michael K Racke; Kathleen Hawker; Federica Agosta; Maria Pia Sormani; Massimo Filippi; Elliot M Frohman
Journal: Ther Adv Neurol Disord Date: 2010-01 Impact factor: 6.570

2. A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis.

Authors: Elliot M Frohman; Gary Cutter; Gina Remington; Hongjiang Gao; Howard Rossman; Bianca Weinstock-Guttman; Jacqueline E Durfee; Amy Conger; Ellen Carl; Katherine Treadaway; Eric Lindzen; Amber Salter; Teresa C Frohman; Anjali Shah; Angela Bates; Jennifer L Cox; Michael G Dwyer; Olaf Stüve; Benjamin M Greenberg; Michael K Racke; Robert Zivadinov
Journal: Ther Adv Neurol Disord Date: 2010-01 Impact factor: 6.570

3. Two strikes against mycophenolate mofetil therapy for myasthenia gravis.

Authors: Michio Hirano
Journal: Curr Neurol Neurosci Rep Date: 2009-01 Impact factor: 5.081

4. Mycophenolate mofetil as second line immunosuppressant in Myasthenia gravis--a long-term prospective open-label study.

Authors: F Hanisch; M Wendt; S Zierz
Journal: Eur J Med Res Date: 2009-08-12 Impact factor: 2.175

Review 5. Advances in myasthenia gravis.

Authors: Emma Ciafaloni; Donald B Sanders
Journal: Curr Neurol Neurosci Rep Date: 2002-01 Impact factor: 5.081

Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil.

1. A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing-remitting multiple sclerosis (TIME MS).

2. A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis.

3. Two strikes against mycophenolate mofetil therapy for myasthenia gravis.

4. Mycophenolate mofetil as second line immunosuppressant in Myasthenia gravis--a long-term prospective open-label study.

Review 5. Advances in myasthenia gravis.

6. Immunosuppression in Multiple Sclerosis and Other Neurologic Disorders.

7. Mycophenolate mofetil for myasthenia gravis: a clear and present controversy.

Review 8. Current Treatment of Myasthenia Gravis.